Memento launches $93M bispecific bet against retinal disease standard
Memento Medicines raised $93M to develop MMT-205, a dual-mechanism antibody challenging anti-VEGF monotherapy dominance in nAMD and DME markets worth billions annually.
Neomorph Closes $100M Series B With First Patient Dosed
Neomorph raised $100M in Series B funding to advance NEO-811, a molecular glue degrader with a first-in-human patient already dosed in Phase 1/2 trials for renal cancer, backed by Deerfield Management and pharma giants Novo Nordisk, Biogen, and AbbVie.